PLPL (Plandai Biotechnology) Equity-to-Asset: 0.00 (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Plandai Biotechnology Equity-to-Asset?

Plandai Biotechnology PLPL -90.00% Equity-to-Asset is 0.00 as of Jun. 2023.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Plandai Biotechnology's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-0.44 Mil. Plandai Biotechnology's Total Assets for the quarter that ended in Jun. 2023 was $0.00 Mil.

The historical rank and industry rank for Plandai Biotechnology's Equity-to-Asset or its related term are showing as below:

PLPL's Equity-to-Asset is not ranked *
in the Business Services industry.
Industry Median: 0.52
* Ranked among companies with meaningful Equity-to-Asset only.

Plandai Biotechnology  (OTCPK:PLPL) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Plandai Biotechnology Equity-to-Asset Related Terms

Plandai Biotechnology Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for Plandai Biotechnology's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Plandai Biotechnology Equity-to-Asset Chart

Plandai Biotechnology Annual Data
Trend Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.30 -0.77 -1.52 0.00 0.00

Plandai Biotechnology Semi-Annual Data
Mar03 Mar04 Mar05 Mar06 Mar07 Mar08 Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.77 -1.52 0.00 0.00

PLPL vs CRGH, TCRI, MAYX: Equity-to-Asset Comparison

For the Specialty Business Services subindustry, Plandai Biotechnology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Plandai Biotechnology Equity-to-Asset vs Business Services Industry

For the Business Services industry and Industrials sector, Plandai Biotechnology's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Plandai Biotechnology's Equity-to-Asset falls into.


Plandai Biotechnology Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Plandai Biotechnology's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )=Total Stockholders Equity/Total Assets
=-0.443/0
=

Plandai Biotechnology's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )=Total Stockholders Equity/Total Assets
=-0.443/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of 0.00 mean?
Plandai Biotechnology (PLPL) has a Equity-to-Asset of 0.00 as of Jun. 2023. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Plandai Biotechnology and its competitors.
Is Plandai Biotechnology's Equity-to-Asset too high?
Plandai Biotechnology's current Equity-to-Asset is 0.00.
How does Plandai Biotechnology's Equity-to-Asset compare to CRGH and TCRI?
Plandai Biotechnology's Equity-to-Asset of 0.00 can be compared against companies in the Business Services industry. The industry median Equity-to-Asset is 0.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Business Services company?
The median Equity-to-Asset among Business Services companies is 0.52, based on 1,097 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Plandai Biotechnology and its competitors. For the Business Services industry, the median Equity-to-Asset is 0.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Plandai Biotechnology's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plandai Biotechnology stock overvalued right now?
Plandai Biotechnology (PLPL) has a current Equity-to-Asset of 0.00. The current Equity-to-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Plandai Biotechnology (PLPL), the current Equity-to-Asset is 0.00 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Plandai Biotechnology Business Description

Address Xinyi Road, Sector 5, No. 7, 57th Floor - 1, Xinyi District, Taipei, TWN, 330
Plandai Biotechnology Inc is engaged in catering and catering management operations in Taiwan.